Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies.

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Its increasing prevalence, particularly among the elderly, renders it one of the most serious current medical epidemics. Several management questions confront the clinician treating a patient with AF: Should the condition be treated? Is the patient at risk of death or serious morbidity as a result of this diagnosis? If treatment is necessary, is rate control or rhythm control superior? Which patients need anticoagulation therapy, and for how long? This review of articles obtained by a search of the PubMed and MEDLINE databases presents the available evidence that can guide the clinician in answering these questions. After discussing the merits of available therapy, including medications aimed at controlling rate, rhythm, or both, we focus on the present status of ablative therapy for AF. Catheter ablation, particularly targeting the pulmonary veins, is being increasingly performed, although the precise indications for this approach and its effectiveness and safety are being actively investigated. We briefly discuss other invasive options that are less frequently used, such as pacemakers, defibrillators, left atrial appendage closure devices, and the surgical maze procedure.

[1]  Charles J Bruce,et al.  Dynamic changes of left ventricular performance and left atrial volume induced by the mueller maneuver in healthy young adults and implications for obstructive sleep apnea, atrial fibrillation, and heart failure. , 2008, The American journal of cardiology.

[2]  P. Vestergaard,et al.  Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. , 2005, The American journal of clinical nutrition.

[3]  Hakan Oral,et al.  Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation , 2002, Circulation.

[4]  M. Pfeffer,et al.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, Journal of the American College of Cardiology.

[5]  J Clémenty,et al.  Radiofrequency ablation for atrial fibrillation , 2003 .

[6]  O. Benavente,et al.  Increased Risk of Intracranial Hemorrhage when Aspirin Is Combined with Warfarin: A Meta-Analysis and Hypothesis , 1999, Cerebrovascular Diseases.

[7]  S. Connolly,et al.  Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. , 2005, American Heart Journal.

[8]  L. Goldman,et al.  Supraventricular Arrhythmia in Patients Having Noncardiac Surgery: Clinical Correlates and Effect on Length of Stay , 1998, Annals of Internal Medicine.

[9]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[10]  Is Atrial Fibrillation a Genetic Disease , 2004 .

[11]  Peng-Sheng Chen,et al.  Autonomic nerve activity and atrial fibrillation. , 2007, Heart rhythm.

[12]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[13]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[14]  G. Lip,et al.  Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. , 2008, Journal of the American College of Cardiology.

[15]  W. Manning,et al.  Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. , 1995, Circulation.

[16]  B. Knight,et al.  Electrical and pharmacologic cardioversion for atrial fibrillation. , 2008, The Medical clinics of North America.

[17]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[18]  P. Wolf,et al.  Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. , 1985, JAMA.

[19]  J. Thomas,et al.  Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. , 1995, American heart journal.

[20]  J. W. Kinch,et al.  Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies. , 1995, Archives of internal medicine.

[21]  M. Earley,et al.  Catheter ablation of permanent atrial fibrillation: medium term results , 2005, Heart.

[22]  Mandeep Bhargava,et al.  Pulmonary Vein Stenosis After Radiofrequency Ablation of Atrial Fibrillation: Functional Characterization, Evolution, and Influence of the Ablation Strategy , 2003, Circulation.

[23]  H. Nathan,et al.  The junction between the left atrium and the pulmonary veins. An anatomic study of human hearts. , 1966, Circulation.

[24]  P. Schweitzer,et al.  Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. , 1998, The American journal of cardiology.

[25]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[26]  W. Lehmacher,et al.  Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial , 2004, Circulation.

[27]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[28]  P. McCarthy,et al.  Atrial fibrillation in patients with coronary disease , 2007, Journal of Interventional Cardiac Electrophysiology.

[29]  M. Franz,et al.  Risk of Stroke in Patients With Atrial Flutter , 2001 .

[30]  A. Capucci,et al.  Dronedarone for prevention of atrial fibrillation: a dose-ranging study. , 2003, European heart journal.

[31]  K. Arakawa,et al.  Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. , 2003, Journal of the American College of Cardiology.

[32]  W. Abelmann,et al.  PATIENTS WITH MITRAL STENOSIS AND SYSTEMIC EMBOLI; HEMODYNAMIC AND CLINICAL OBSERVATIONS. , 1964, Archives of internal medicine.

[33]  M. Hocini,et al.  Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation. , 2005, Heart rhythm.

[34]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[35]  N. Samani,et al.  The effect of preoperative atrial fibrillation on survival following mitral valve repair for degenerative mitral regurgitation. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[36]  S. Lévy Do we need pharmacological therapy for atrial fibrillation in the ablation era? , 2007, Journal of Interventional Cardiac Electrophysiology.

[37]  C. Hamm,et al.  Usefulness of Atrial Fibrillation Burden as a Predictor for Success of Pulmonary Vein Isolation , 2005, Pacing and clinical electrophysiology : PACE.

[38]  KikuoArakawa,et al.  Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation , 2000 .

[39]  Y. Blaauw,et al.  Atrial fibrillation: insights from clinical trials and novel treatment options , 2007, Journal of internal medicine.

[40]  S. Asirvatham Pulmonary vein-related maneuvers: part I. , 2007, Heart rhythm.

[41]  A. Sheikhzadeh,et al.  Detection of a Hypercoagulable State in Nonvalvular Atrial Fibrillation and the Effect of Anticoagulant Therapy , 1996, Thrombosis and Haemostasis.

[42]  O. Alfieri,et al.  Atrial Electroanatomic Remodeling After Circumferential Radiofrequency Pulmonary Vein Ablation: Efficacy of an Anatomic Approach in a Large Cohort of Patients With Atrial Fibrillation , 2001, Circulation.

[43]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[44]  M. Enriquez-Sarano,et al.  Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. , 2002, Journal of the American College of Cardiology.

[45]  V. Somers,et al.  Atrial fibrillation and obesity--results of a meta-analysis. , 2008, American heart journal.

[46]  J. Macgregor,et al.  The effects of rate and irregularity on sympathetic nerve activity in human subjects. , 2007, Heart rhythm.

[47]  D. Packer,et al.  Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation , 2008, Journal of Interventional Cardiac Electrophysiology.

[48]  A. Nogami,et al.  Segmental pulmonary vein isolation for paroxysmal atrial fibrillation improves quality of life and clinical outcomes. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[49]  T. Arentz,et al.  Incidence of pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory atrial fibrillation. , 2003, European heart journal.

[50]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[51]  D. Mehta,et al.  Thromboembolism following cardioversion of "common" atrial flutter. Risk factors and limitations of transesophageal echocardiography. , 1996, Chest.

[52]  C. Hamm,et al.  Asymptomatic recurrences of atrial fibrillation after pulmonary vein isolation. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[53]  T. Asano,et al.  Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation. , 2007, Journal of cardiology.

[54]  Stroke Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.

[55]  F. Morady,et al.  Prevalence of Asymptomatic Recurrences of Atrial Fibrillation After Successful Radiofrequency Catheter Ablation , 2004, Journal of cardiovascular electrophysiology.

[56]  R. Page,et al.  Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. , 1994, Circulation.

[57]  EmileDaoud,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation , 2008 .

[58]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[59]  S. Mouly,et al.  Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. , 2007, The Cochrane database of systematic reviews.

[60]  M. Chung,et al.  Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. , 2005, American heart journal.

[61]  G. Lip,et al.  Tedisamil: a new novel antiarrhythmic , 2004, Expert Opinion on Investigational Drugs.

[62]  E. Mascha,et al.  Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. , 2007, Journal of cardiothoracic and vascular anesthesia.

[63]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[64]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomised trial , 2001 .

[65]  P. Tchou,et al.  Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation: impact of different catheter technologies. , 2002, Journal of the American College of Cardiology.

[66]  Sonia S Anand,et al.  Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.

[67]  R. Hart,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 2000 .

[68]  B. Horne,et al.  Frequency of elevation of C-reactive protein in atrial fibrillation. , 2004, The American journal of cardiology.

[69]  M. Coceani,et al.  Catheter Ablation of Long‐Lasting Persistent Atrial Fibrillation: Clinical Outcome and Mechanisms of Subsequent Arrhythmias , 2006, Journal of cardiovascular electrophysiology.

[70]  Bartley P Griffith,et al.  Predictors and impact of atrial fibrillation after isolated coronary artery bypass grafting , 2002, Critical care medicine.

[71]  O. Alfieri,et al.  Atrio-Esophageal Fistula as a Complication of Percutaneous Transcatheter Ablation of Atrial Fibrillation , 2004, Circulation.

[72]  G. Hutchins,et al.  The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. , 1994, Journal of the American College of Cardiology.

[73]  J. Halperin,et al.  "Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. , 2008, Journal of the American College of Cardiology.

[74]  Tong Liu,et al.  Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. , 2008, International journal of cardiology.

[75]  L. Frost,et al.  Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. , 2000, The American journal of medicine.

[76]  D. Packer,et al.  Clinical Presentation, Investigation, and Management of Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation , 2005, Circulation.

[77]  Jonathan H Seltzer,et al.  The Diagnosis of Cardiac Arrhythmias: A Prospective Multi‐Center Randomized Study Comparing Mobile Cardiac Outpatient Telemetry Versus Standard Loop Event Monitoring , 2007, Journal of cardiovascular electrophysiology.

[78]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[79]  M. Ezekowitz,et al.  Alternate-day dosing of aspirin in atrial fibrillation: A critical evaluation. , 1999, American heart journal.

[80]  N. Lakkis,et al.  Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. , 2007, Journal of the American College of Cardiology.

[81]  I. Khan Atrial stunning: determinants and cellular mechanisms. , 2003, American heart journal.

[82]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach , 2005 .

[83]  Claus Schmitt,et al.  Freedom From Atrial Tachyarrhythmias After Catheter Ablation of Atrial Fibrillation: A Randomized Comparison Between 2 Current Ablation Strategies , 2005, Circulation.

[84]  Prashanthan Sanders,et al.  Localized Sources Maintaining Atrial Fibrillation Organized by Prior Ablation , 2006, Circulation.

[85]  Shih-AnnChen,et al.  Alterations of Heart Rate Variability After Radiofrequency Catheter Ablation of Focal Atrial Fibrillation Originating From Pulmonary Veins , 1999 .

[86]  M. P. van den Berg,et al.  C-reactive protein and microalbuminuria are associated with atrial fibrillation. , 2005, International journal of cardiology.

[87]  W. E. Kemp,et al.  Pulmonary vein stenosis after catheter ablation of atrial fibrillation. , 1998, Circulation.

[88]  M. Hennersdorf,et al.  Prevalence of Paroxysmal Atrial Fibrillation Depending on the Regression of Left Ventricular Hypertrophy in Arterial Hypertension , 2007, Hypertension Research.

[89]  A. Waldo The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre st , 2007 .

[90]  J. Svendsen,et al.  Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. , 2006, American heart journal.

[91]  C. Otto,et al.  Valvular aortic stenosis: disease severity and timing of intervention. , 2006, Journal of the American College of Cardiology.

[92]  A Laupacis,et al.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. , 1995, Archives of internal medicine.

[93]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[94]  T. W. Mattingly,et al.  Systemic arterial embolism in rheumatic heart disease. , 1951, American heart journal.

[95]  T. Kural,et al.  Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. , 1996, The American journal of cardiology.

[96]  H. Nakagawa,et al.  Electrical Stimulation to Identify Neural Elements on the Heart: Their Role in Atrial Fibrillation , 2005, Journal of Interventional Cardiac Electrophysiology.

[97]  H. Oral,et al.  Postoperative atrial fibrillation. , 2009, Cardiology clinics.

[98]  K. Yokoyama,et al.  Localization of left atrial autonomic ganglionated plexuses using endocardial and epicardial high frequency stimulation in patients with atrial fibrillation , 2005 .

[99]  Douglas L Packer,et al.  Progress in Nonpharmacologic Therapy of Atrial Fibrillation , 2003, Journal of cardiovascular electrophysiology.

[100]  B. Gersh,et al.  The Natural History of Lone Atrial Flutter , 2004, Annals of Internal Medicine.

[101]  W. Manning,et al.  Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. , 1995, The American journal of cardiology.

[102]  M. Eliasziw,et al.  Occurrence of Hemispheric and Retinal Ischemia in Atrial Fibrillation Compared With Carotid Stenosis , 2002, Stroke.

[103]  M. Di leo,et al.  Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. , 1999, The American journal of cardiology.

[104]  V. Santinelli,et al.  A randomized study of prophylactic catheter ablation in asymptomatic patients with the wolff-parkinson-white syndrome , 2004 .

[105]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[106]  D. Lappé,et al.  Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. , 2005, Journal of cardiovascular electrophysiology.

[107]  R Lazzara,et al.  Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation , 2000, Circulation.

[108]  U. Tebbe,et al.  Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. , 2003, Journal of the American College of Cardiology.

[109]  C. Tai,et al.  Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. , 1999, Circulation.

[110]  J. Franklyn,et al.  Association between serum free thyroxine concentration and atrial fibrillation. , 2007, Archives of internal medicine.

[111]  E. Ellerbeck,et al.  Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients , 2004, Stroke.

[112]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[113]  R. Hart Stroke prevention in atrial fibrillation , 2000, Current cardiology reports.

[114]  J. Auer,et al.  Subclinical hyperthyroidism as a risk factor for atrial fibrillation. , 2001, American heart journal.

[115]  P. Howard,et al.  Potential Use of Statins to Prevent Atrial Fibrillation After Coronary Artery Bypass Surgery , 2008, The Annals of pharmacotherapy.

[116]  F. Morady,et al.  Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. , 1996, The American journal of cardiology.

[117]  Jeremy N Ruskin,et al.  Three‐Dimensional Analysis of Pulmonary Venous Ostial and Antral Anatomy: Implications for Balloon Catheter‐Based Pulmonary Vein Isolation , 2006, Journal of cardiovascular electrophysiology.

[118]  B. Gersh,et al.  Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation: A 30-Year Follow-Up Study , 2007, Circulation.

[119]  J Clémenty,et al.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation. , 1997, Circulation.

[120]  Ralph B. D'Agostino,et al.  Parental Atrial Fibrillation as a Risk Factor for Atrial Fibrillation in Offspring , 2004 .

[121]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[122]  D. Fatkin,et al.  Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. , 1994, Journal of the American College of Cardiology.

[123]  E L Pritchett,et al.  Observations on the transition from intermittent to permanent atrial fibrillation. , 2000, American heart journal.

[124]  M. Horlitz,et al.  Atrio-oesophageal fistula following circumferential pulmonary vein ablation: verification of diagnosis with multislice computed tomography. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[125]  M. Mansour,et al.  Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. , 2002, Cardiovascular research.

[126]  V. Santinelli,et al.  A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. , 2006, Journal of the American College of Cardiology.

[127]  A. Terzic,et al.  KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation , 2007, Nature Clinical Practice Cardiovascular Medicine.

[128]  G. Lip,et al.  Atrial fibrillation and stroke prevention , 2007, The Lancet Neurology.

[129]  M. Allessie,et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. , 1995, Circulation.

[130]  J Clémenty,et al.  Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. , 2000, Circulation.

[131]  F. Morady,et al.  Risk of Thromboembolic Events After Percutaneous Left Atrial Radiofrequency Ablation of Atrial Fibrillation , 2006, Circulation.

[132]  S. Hohnloser,et al.  Drug therapy , 2022 .

[133]  G. Boriani,et al.  Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long‐term outcome , 2007, International journal of clinical practice.

[134]  R. Page,et al.  Effect of Atrial Fibrillation and an Irregular Ventricular Response on Sympathetic Nerve Activity in Human Subjects , 2003, Circulation.

[135]  Douglas Packer,et al.  Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation.

[136]  L. Kuller,et al.  Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. , 2007, American heart journal.

[137]  D. Shah,et al.  Catheter Ablation of Chronic Atrial Fibrillation Targeting the Reinitiating Triggers , 2000, Journal of cardiovascular electrophysiology.

[138]  L. Poller,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. , 1993, The New England journal of medicine.

[139]  R. Page,et al.  Asymptomatic atrial fibrillation. , 2005, Progress in cardiovascular diseases.

[140]  M. Nakagawa,et al.  Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. , 1988, Japanese circulation journal.

[141]  R. Roberts Mechanisms of Disease: genetic mechanisms of atrial fibrillation , 2006, Nature Clinical Practice Cardiovascular Medicine.

[142]  J. Gore,et al.  Magnitude of and Risk Factors for In-Hospital and Postdischarge Stroke in Patients With Acute Coronary Syndromes: Findings From a Global Registry of Acute Coronary Events , 2005, Circulation.

[143]  S. Mouly,et al.  Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.

[144]  F. Gaita,et al.  Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications , 2007, Journal of cardiovascular medicine.

[145]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[146]  C. Tracy,et al.  American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.

[147]  C. Tai,et al.  Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. , 1999, Circulation.

[148]  Cynthia A. Carnes,et al.  C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.

[149]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[150]  E. Sosa,et al.  Left Atrial‐Esophageal Fistula Complicating Radiofrequency Catheter Ablation of Atrial Fibrillation , 2005, Journal of cardiovascular electrophysiology.

[151]  D. Levy,et al.  Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. , 2004, The American journal of cardiology.

[152]  M A Waclawiw,et al.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[153]  J. Molnar,et al.  Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: A Systematic Review and Meta-Analysis , 2008, American journal of therapeutics.

[154]  Bruce M Psaty,et al.  Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.

[155]  W. Decker,et al.  Management of atrial fibrillation in the emergency department. , 2005, Emergency medicine clinics of North America.

[156]  A. Massumi,et al.  Stroke prevention in nonvalvular atrial fibrillation. , 2011, Texas Heart Institute journal.

[157]  K. Nademanee,et al.  A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. , 2004, Journal of the American College of Cardiology.

[158]  StanleyNattel,et al.  Omega-3 Polyunsaturated Fatty Acids Prevent Atrial Fibrillation Associated With Heart Failure but Not Atrial Tachycardia Remodeling , 2007 .

[159]  W. Rheinboldt,et al.  A COMPUTER MODEL OF ATRIAL FIBRILLATION. , 1964, American heart journal.

[160]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[161]  V. Barriales,et al.  Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. , 1999, American heart journal.

[162]  S. Asirvatham Pacing maneuvers for nonpulmonary vein sources: part II. , 2007, Heart rhythm.

[163]  W. Saliba,et al.  Brief Communication: AtrialEsophageal Fistulas after Radiofrequency Ablation , 2006, Annals of Internal Medicine.

[164]  C. Israel,et al.  Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. , 2004, Journal of the American College of Cardiology.

[165]  O. Orning,et al.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.

[166]  P. Box Corticosteroids for the prevention of atrial fibrillation after cardiac surgery:A randomized controlled trial , 2007 .

[167]  Antonio De Simone,et al.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). , 2006, European heart journal.

[168]  C. White,et al.  Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter , 2007, The Annals of pharmacotherapy.

[169]  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2002 .

[170]  Gregory Y H Lip,et al.  Quality of life in patients with atrial fibrillation: a systematic review. , 2006, The American journal of medicine.

[171]  Xu-Fang Yu Association of atrial fibrillation and obstructive sleep apnea , 2011 .

[172]  S. Hohnloser,et al.  Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. , 2004, Journal of the American College of Cardiology.

[173]  A. Keech,et al.  Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. , 2006, European heart journal.